INTS

Intensity Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website intensitytherapeutics.com
Employees(FY) -
ISIN US45828J1034

Performance

+30.05%

1W

+19.27%

1M

+63.0%

3M

+132.86%

6M

-42.94%

YTD

-17.95%

1Y

Profile

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company was incorporated in 2012 and is headquartered in Westport, Connecticut.

Advanced Technical Analysis

Technical Analysis of INTS 2024-05-10

Overview:

In analyzing the technical indicators for INTS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Indicators:

Moving Averages (MA): The 5-day MA has been below the closing price, indicating a s...

See more ...

Recent News & Updates

2024-05-14 20:01
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors(Prnewswire)
2024-05-09 22:48
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial(Yahoo Finance)
2024-05-09 20:01
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate(Prnewswire)
2024-05-09 11:54
INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-09 04:08
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-04-01 20:01
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024(Prnewswire)
2024-03-26 11:53
INTS Stock Earnings: Intensity Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-25 20:01
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares(Globenewswire)
2024-03-14 04:09
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update(Prnewswire)
2024-03-13 20:00
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024(Prnewswire)
2024-02-20 19:01
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference(Prnewswire)
2024-01-02 19:01
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program(Prnewswire)
2023-12-11 19:01
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer(Prnewswire)
2023-12-07 22:12
Why Is Intensity Therapeutics (INTS) Stock Up 133% Today?(Investorplace)
2023-12-07 19:30
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS(Prnewswire)
2023-11-30 19:01
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium(Prnewswire)
2023-11-12 19:01
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update(Prnewswire)
2023-11-01 19:01
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023(Prnewswire)
2023-09-06 20:01
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma(Yahoo Finance)
2023-09-04 20:01
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-13 19:01
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update(Yahoo Finance)
2023-08-06 19:01
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update(Yahoo Finance)
2023-07-31 04:05
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update(Yahoo Finance)
2023-07-09 20:00
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds(Yahoo Finance)
2023-07-05 04:15
Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds(Yahoo Finance)
2023-06-29 08:00
Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds(Yahoo Finance)

Page 1 of 1

previousnext